**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 83685

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Clinical significance and potential application of cuproptosis-related genes in gastric cancer**

Yan JN *et al*. Cuproptosis-related genes in gastric cancer

Jia-Ning Yan, Li-Hua Guo, Dan-Ping Zhu, Guo-Liang Ye, Yong-Fu Shao, Han-Xuan Zhou

**Jia-Ning Yan, Li-Hua Guo, Dan-Ping Zhu, Guo-Liang Ye, Yong-Fu Shao,** Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China

**Han-Xuan Zhou,** Department of Pharmacy, Yinzhou Integrated TCM and Western Medicine Hospital, Ningbo 315000, Zhejiang Province, China

**Author contributions:** Yan JN designed and performed the research and wrote the paper; Shao YF and Ye GL designed the research and supervised the report; Zhou HX and Guo LH designed the research and contributed to the analysis; Shao YF and Zhu DP were responsible for the revision of the manuscript for important intellectual content; All authors expressed approval of the final version to be submitted.

**Supported by** The Key Scientific and Technological Projects of Ningbo, No. 2021Z133.

**Corresponding author: Yong-Fu Shao, MD, PhD, Doctor,** Department of Gastroenterology, The First Affiliated Hospital of Ningbo University, No. 247 Renmin Road, Ningbo 315000, Zhejiang Province, China. fyshaoyongfu@nbu.edu.cn

**Received:** February 4, 2023

**Revised:** March 28, 2023

**Accepted:** May 6, 2023

**Published online:** June 15, 2023

**Abstract**

BACKGROUND

Worldwide, gastric cancer (GC) is a common lethal solid malignancy with a poor prognosis. Cuproptosis is a novel type of cell death mediated by protein lipoylation and may be related to GC prognosis.

AIM

To offer new insights to predict GC prognosis and provide multiple therapeutic targets related to cuproptosis-related genes (CRGs) for future therapy.

METHODS

We collected data from several public data portals, systematically estimated the expression level and prognostic values of CRGs in GC samples, and investigated related mechanisms using public databases and bioinformatics.

RESULTS

Our results revealed that *FDX1*, *LIAS*, and *MTF1* were differentially expressed in GC samples and exhibited important prognostic significance in The Cancer Genome Atlas (TCGA) cohort. We constructed a nomogram model for overall survival and disease-specific survival prediction and validated it *via* calibration plots. Mecha-nistically, immune cell infiltration and DNA methylation prominently affected the survival time of GC patients. Moreover, protein-protein interaction network, KEGG pathway and gene ontology enrichment analyses demonstrated that *FDX1*, *LIAS*, *MTF1* and related proteins play key roles in the tricarboxylic acid cycle and cuproptosis. Gene Expression Omnibus database validation showed that the expression levels of *FDX1*, *LIAS*, and *MTF1* were consistent with those in the TCGA cohort. Top 10 perturbagens has been filtered by Connectivity Map.

CONCLUSION

In conclusion, *FDX1*, *LIAS*, and *MTF1* could serve as potential prognostic biomarkers for GC patients and provide novel targets for immunotarget therapy.

**Key Words:** Cuproptosis; Prognosis; Gastric cancer; Biomarker; Nomogram; Bioinformatics

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: Yan JN, Guo LH, Zhu DP, Ye GL, Shao YF, Zhou HX. Clinical significance and potential application of cuproptosis-related genes in gastric cancer. *World J Gastrointest Oncol* 2023; 15(7): 1200-1214

**URL**: https://www.wjgnet.com/1948-5204/full/v15/i7/1200.htm

**DOI**: https://dx.doi.org/10.4251/wjgo.v15.i7.1200

**Core Tip:** In this study, the molecular biological mechanisms of cuproptosis-related genes (CRGs) were explored in gastric cancer, and clinical prognostic models for gastric cancer treatment were constructed by interactively analysing the links among CRGs and clinical information using bioinformatics. We constructed a significant prognostic nomogram model for gastric cancer and found that *FDX1*, *LIAS*, and *MTF1* could serve as potential prognostic biomarkers for gastric cancer patients and provide novel targets for immunotarget therapy.

**INTRODUCTION**

Currently, gastric cancer (GC) is a common malignant tumour with a high incidence and mortality rate worldwide, imposing a substantial economic burden on society[1]. The detailed pathogenesis of GC is currently unclear, and more than 35% of patients are initially diagnosed with distant metastasis and poor prognosis[2]. Although novel treatments, such as chemotherapy, surgery, radiotherapy and combination therapy, are constantly being updated, the prognosis of GC patients remains suboptimal[3]. Hence, it is urgent to understand the molecular mechanisms of GC and establish an effective prognostic model for clinical application.

Copper is an important cofactor for essential enzymes, and dysregulation of copper homeostasis can trigger cytotoxicity. Recent research points out that copper ionophores induce a distinct form of regulated cell death mediated by protein lipoylation of the tricarboxylic acid (TCA) cycle[4]. This special process is also called cuproptosis. Moreover, lipoylated proteins are tightly associated with a variety of human tumours, and cells with high levels of lipoylated proteins are sensitive to cuproptosis, which suggests that cuproptosis is strongly correlated with the biological behaviour of malignant tumour cells[4]. Additionally, it has been confirmed that abnormalities in intermediates in the TCA cycle are related to mitochondrial functions and GC morbidity[5]. All of this evidence suggests that cuproptosis influences the development and distal survival time of GC patients.

In our study, we systematically analysed the molecular alterations in cuproptosis-related genes (CRGs) and constructed a novel prognostic nomogram model in GC using bioinformatics technology. Our findings offer new insights into predicting GC prognosis and provide multiple therapeutic targets for future therapy.

**MATERIALS AND METHODS**

***Data source retrieval and processing***

We chose several open-source databases to retrieve the expression profiles, clinical information and survival data of GC and normal tissues, such as The Cancer Genome Atlas (TCGA) database (https://genome-cancer.ucsc.edu/) and the Genotype-Tissue Expression (GTEx) project. A total of 414 GC samples, 36 adjunct nontumor samples and 174 normal tissues were analysed in this study. All data were available in public open-access databases, and additional approval from the local ethics committee was not needed.

***Analysis of differentially expressed and prognosis-related CRGs***

After a literature search, we selected 19 genes (*ATP7A*, *ATP7B*, *CDKN2A*, *DBT*, *DLAT*, *DLD*, *DLST*, *FDX1*, *GCSH*, *GLS*, *LIAS*, *LIPT1*, *LIPT2*, *MTF1*, *NFE2L2*, *NLRP3*, *PDHA1*, *PDHB*, *SLC31A1*) that function closely with cuproptosis[4]. We first compared the differentially expressed CRGs in GC from the TCGA cohort and in normal tissues in the GTEx cohort using the R statistical computing environment (3.6.3; R Foundation for Statistical Computing). *P* < 0.05 was considered statistically significant. We logged into the cBioPortal website (https://www.cbioportal.org/) and surveyed the mutation information for differentially expressed CRGs in GC[6].

Cox proportional hazards regression was performed to filter the prognosis-related genes, and *P* < 0.2 was considered statistically significant in the multivariate Cox proportional hazards regression model.

***Survival analysis and nomogram construction using prognosis-related CRGs***

We first calculated the risk score for each sample using regression coefficients to identify the prognostic signature of CRGs for overall survival (OS) and disease-specific survival (DSS). The patients were further divided into high-risk and low-risk groups according to the median risk score. Subsequently, we analysed the survival data for each prognosis-related CRG in the high-risk and low-risk groups using the Kaplan-Meier method *via* the R package survival v 3.2-10.

Moreover, we established an OS and DSS nomogram model based on these prognosis-related CRGs. The concordance index (C-index) was used to obtain the discrimination of the nomogram, and calibration plots were generated to display the association between the predicted and observed risk results.

***Methylation analysis of prognosis-related CRGs***

Methylation analysis of prognosis-related CRGs was performed *via* Methsurv (https://biit.cs.ut.ee/methsurv/), a web tool to perform multivariable survival analysis using DNA methylation data[7-9].

***Analysis of the association between prognosis-related CRGs and immune infiltration***

We determined the survival significance of prognosis-related CRGs and the immune infiltration levels of several immune cell types. Survival Genie is a web tool used to perform survival analysis of single-cell RNA-seq data and a variety of other molecular inputs for several cancer types[10]. We first applied Survival Genie to investigate correlations between prognosis-related CRGs and immune infiltration levels. Then, we detected the immune infiltration level of multifarious immune cells in the TCGA cohort using the R package “GSVA”[11]. TIMER, an online portal for systematic analysis of immune infiltrates across diverse cancer types (http://timer.cistrome.org), was used to validate the results[12-14]. Spearman’s correlation analysis was performed to determine the association between quantitative variables.

***Functional analysis of prognosis-related CRGs***

The GeneMANIA prediction server is a web interface for generating hypotheses about biological network integration for gene prioritization and predicting gene function[15]. We input the prognosis-related CRGs and output the nearest gene for each locus. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) website (https://string-db.org/) contains various protein-protein correlation data, which were used to build a prognosis-related CRG interacting protein-protein interaction (PPI) network. A confidence score > 0.7 was considered significant[16]. We input the genes preserved from GeneMANIA and output the networks. The nodes in the PPI network were further used to perform KEGG pathway enrichment analysis and gene ontology (GO) classification *via* the R packages “clusterProfiler” and “ggplot2”. A *P* value < 0.05, min enrichment > 3, and min overlap > 3 were considered significant[17]. Connectivity Map (https://clue.io/, CMap) is a systematic tool to discover functional connections among diseases and was utilized to find perturbagens to the expression of CRGs[18-20]. We selected the “Query” module and further filtered the top 10 perturbagens of “FDR\_q\_nlog 10” with an explicit “moa”.

***Differential expression validation of prognosis-related CRGs***

The TNM plot is a web tool from the National Center for Biotechnology Information (www.tnmplot.com) used for comparison of gene expression in various tumours[21]. We chose the “compare Tumour and Normal” and “Gene chip data” modules for validation using Gene Expression Omnibus (GEO) samples. *P* < 0.05 was deemed statistically significant.

**RESULTS**

***Differential expression and genetic alterations of CRGs in GC***

As previously mentioned, we contrasted the expression levels of CRGs in the GC cohort displayed in Figure 1A. We found that *ATP7A*, *ATP7B*, *CDKN2A*, *DLAT*, *DLD*, *FDX1*, *GCSH*, *GLS*, *LIAS*, *LIPT1*, *LIPT2*, *MTF1*, *NFE2L2*, *NLRP3*, *PDHA1*, *PDHB*, and *SLC31A1* were differentially expressed in GC (*P* < 0.05). Then, we performed coexpression analysis of these CRGs and visualized them *via* a heatmap, which showed a high correlation (Figure 1B). For example, *FDX1* was significantly positively associated with *LIAS* and negatively associated with *MTF1*.

Furthermore, we determined the gene mutation patterns of these CRGs in GC. The overall mutation landscape is shown in Figure 1C, and we list the particular patterns of each gene mutation in Figure 1D.

***Identification of prognosis-related CRGs and survival analysis***

We further investigated the relationship between the expression of CRGs and prognosis in GC samples. We first constructed a multivariable Cox regression model to estimate the roles of CRGs in OS and DSS in the TCGA cohort. Our results showed that *FDX1* (*P* = 0.059) and *MTF1* (*P* = 0.088) were remarkably associated with OS in GC samples, as shown in Table 1. Similarly, *FDX1* (*P* = 0.181), *LIAS* (*P* = 0.045), and *MTF1* (*P* = 0.117) were remarkably associated with DSS in GC samples, as shown in Table 2. Hence, we selected *FDX1*, *LIAS*, and *MTF1* as prognosis-related CRGs. The clinical information for *FDX1*, *LIAS*, and *MTF1* in the TCGA cohort is shown in Supplementary Tables 1-3.

According to the outcomes of the Cox regression model, we used regression coefficients to build the OS/DSS risk score model. Risk score OS = -0.308 × *FDX1* - 0.413 × *MTF1* + 2.812. Risk score DSS = -0.373 × *FDX1* - 0.601 × *LIAS* - 0.413 × *MTF1* + 3.534. We separated the samples into high- and low-risk groups in terms of the risk score displayed in Figure 2A and B. Then, we built a survival curve *via* the Kaplan-Meier method to evaluate the prognostic value for each CRG. Our results suggested that all of these CRGs were prominently associated with OS and DSS in GC (Figure 2C and D), which was in keeping with the previous results.

***Construction of the nomogram and validation in GC***

To better guide clinical application, we generated nomograms from the prognosis-related CRGs and the observed OS and DSS at 1, 3 and 5 years of survival (Figure 3A and B). The C-index was calculated to be 0.673 for OS and 0.623 for DSS. The nomogram calibration curves demonstrated ideal agreement between prediction and observation at 1, 3 and 5 years (Figure 3C and D), indicating that our nomogram models are worthy of a multicentre, prospective clinical study.

***Exploration of the mechanism of CRGs in distal prognosis determination in GC***

The dynamic relationship between malignant tumours and immune cells in the microenvironment plays important roles in cancer development[22]. We evaluated the correlations between *FDX1*, *LIAS*, *MTF1* and distal survival probability from single-cell RNA-seq (scRNA-seq) data using Survival Genie. We found that *FDX1*, *LIAS*, and *MTF1* were remarkably related to survival time, as shown in Figure 4A-C. Then, we investigated the immune cell infiltration level using scRNA-seq data, and our results showed that the expression of *FDX1* was correlated with CD4 T+ memory cells, monocytes, and naive B cells, as shown in Figure 4D. *LIAS* was associated with CD4 T+ memory cells, Tregs, mast cells, NK cells, gamma delta T cells, eosinophils, and naive B cells, as shown in Figure 4E. *MTF1* was significantly related to NK cells, Tregs, neutrophils, monocytes, and activated dendritic cells, as shown in Figure 4E. On this basis, we detected the immune cell infiltration level in GC tissues and visualized the results as lollipop plots in Figure 4F-I. The length of the bars in the lollipop plots is relative to the correlation levels, and the colour of the cycles is relative to the *P* value. Subsequently, we used TIMER to validate our results and found that the expression of *FDX1*, *LIAS*, and *MTF1* and immune infiltration of macrophages were prominently correlated with the OS time of GC patients, which was consistent with our results (Supplementary Figure 1). Meanwhile, higher levels of methylation in *MTF1* and lower levels of methylation in *FDX1*, *LIAS* were associated with poor prognosis in GC patients (Figure 4J-L). All of the evidence suggests that the prognosis-related CRGs can regulate immune cell infiltration and the tumour microenvironment to influence the survival times of GC patients.

***Biofunction analysis of prognosis-related CRGs in GC***

To explore the biofunction of prognosis-related CRGs, we input *FDX1*, *LIAS*, and *MTF1* into GeneMANIA to test their interactions and gathered 23 genes in the network (Figure 5A). Then, we inputted these genes into STRING to investigate the functions of their coding proteins, which were visualized as a PPI network (Figure 5B). Moreover, we performed KEGG pathway enrichment analysis and gene ontology classification to understand the related signalling pathways and biological functions in the PPI network. The results in Figure 5C show that *FDX1*, *LIAS*, and *MTF1* play key roles in prognosis and immune cell infiltration by mediating iron ion binding and mitochondrial metabolism, which are closely associated with the TCA cycle and necroptosis. Furthermore, we performed CMap to explore the top 10 perturbagens to the expression of genes in the PPI network. We compared the expression levels of the genes in the PPI network using the TCGA cohort shown in Supplementary Figure 2 and identified upregulated genes in CMap. Our results revealed that fluconazole, KD-025, and clofarabine may be potential perturbagens of prognostic CRGs (Table 3).

***Validation of FDX1, LIAS, and MTF1 differential expression in GC***

To identify promising prognosis-related CRGs, we validated the expression level using the GEO database for preliminary verification. In the GEO dataset, *FDX1* was remarkably higher in GC patients (*P* = 3.67 × 10-2), and *MTF1* was significantly overexpressed in the GC group (*P* = 7.04 × 10-3). *LIAS* was prominently downregulated in GC samples (*P* < 0.001), which was in line with the TCGA cohort data and revealed the role of *LIAS* as a tumour suppressor gene and the role of *FDX1* and *MTF1* as cancer promotors (Figure 6).

**DISCUSSION**

Despite aggressive multimodal therapy, GC is still a devastating disease with a very poor prognosis[23]. The pathogenesis of GC is complicated, and the in-depth mechanisms and molecular signalling pathways remain to be elucidated. Luckily, the development of bioinformatics can help to open different perspectives on analysing clinical samples from multiple dimensions and improve the efficiency and accuracy of studies focusing on several genes and cancer[24]. Cuproptosis is an unusual mechanism of cell death that is helpful in explaining the pathological mechanisms related to copper overload disease and suggests a new method of treating cancer with copper toxicity[4]. To the best of our knowledge, no previous studies have estimated the relationship between CRGs and the progression of GC. Hence, our study focused on the prognostic signature and explored the biofunction and oncological mechanism of CRGs in GC *via* bioinformatics.

There are distinct advantages in our research. We first filtered the differentially expressed CRGs in the TCGA cohort and defined their prognostic significance *via* multivariable Cox regression and Kaplan-Meier methods. Then, we constructed and validated a nomogram model for clinical application. Moreover, we explored the mechanisms of how prognosis-related CRGs influence distal prognosis at the DNA methylation level and immune cell infiltration level. Finally, we discovered the functions of *FDX1*, *LIAS*, and *MTF1* and validated their differential expression *via* the GEO database.

The prognostic models constructed in our study consist of three CRGs (*FDX1*, *LIAS*, and *MTF1*). *FDX1* has been confirmed to encode a reductase that decreases Cu2+ to its more toxic form, Cu1+. *LIAS* encodes lipoyl synthase, a critical component of the lipoic acid pathway. Deletion of *FDX1* and *LIAS* can confer resistance to copper-induced cell death[4]. Existing studies have revealed that *FDX1* plays a key role in steroidogenesis and mediates ageing and tumour suppression *via* the FDXR-p73 axis[25]. Furthermore, downregulated expression of *FDX1* is correlated with more advanced tumour-node-metastasis stages and poor prognosis in clear cell renal cell carcinoma[26]. Burr *et al*[27] noted that *LIAS* was an important regulator controlling the stability of HIFα and that disruption of *LIAS* decreased the activity of HIFα, which may further facilitate tumour formation[27]. Higher *LIAS* expression was also considered a prognostic biomarker indicating better distant metastasis-free survival time in breast cancer[28]. *MTF1* is a key transcription factor in charge of intracellular zinc efflux associated with the TCA cycle, is overexpressed in glioma and regulates malignant biological behaviours by modulating the TAF15/LINC00665/*MTF1* (YY2)/GTSE1 axis[29]. Similarly, it has been demonstrated that elevated *MTF1* is important for hepatocellular carcinoma tumour growth and migration and is regulated by the METTL3-METTL14-WTAP axis[30]. However, there are few studies on these genes in GC. Our study identified differentially expressed CRGs in GC and assessed their prognostic value and their biofunctions. Additionally, our prognostic model focusing on CRG expression displayed a fantastic performance in survival prediction, which warrants larger sample sizes and longitudinal research.

We further explored the potential mechanisms associated with prognosis in GC. Infiltration of immune cells within the tumour is typically related to distal prognosis and response to immunotherapy[31]. We delineated 22 unique clusters of immune cells in GC *via* scRNA-seq and examination of tissue samples. Our results showed that *FDX1*, *LIAS*, and *MTF1* in scRNA-seq samples affected multiple types of immune cells, such as CD4 T+ memory cells, monocytes, naive B cells, NK cells, and Tregs. Similarly, in GC tissues, these genes impacted Th2 cells, T helper cells, DCs, iDCs, pDCs, B cells, T cells, Tgd cells, and NK cells and thus are important prognostic factors and could be promising targets for conventional immunosuppressant therapy or combination immunosuppression. Likewise, analysis of the levels of DNA methylation also suggested the prognostic significance of *FDX1*, *LIAS* and *MTF1*. The existing results indicate intrinsic connections between DNA methylation and prognosis, which are worthy of further validation.

Moreover, we performed functional analysis of *FDX1*, *LIAS*, and *MTF1* using GeneMANIA, STRING, KEGG pathway enrichment analysis and GO classification. Functional analysis showed that the proteins associated with *FDX1*, *LIAS*, and *MTF1* are involved in the TCA cycle, cuproptosis and several signalling pathways. *FDX1*, *LIAS*, *MTF1* and related genes can modulate the progression of iron ion binding and mitochondrial metabolism to influence the survival time and immune cell infiltration. In addition, it is important to explore biological targets to develop novel drugs, and perturbagens are indispensable mediators in these efforts to discover biological connections[32]. We found 16 upregulated and only 4 downregulated genes detected in the TCGA GC cohort and GTEx cohort; thus, we imported only the overexpressed genes into the CMap tool, which still provided potential opportunities to directly build connections between targets and drugs at the gene transcriptional level.

Finally, we validated the differential expression of *FDX1*, *LIAS*, and *MTF1* in the GEO database to make our results more robust. Interestingly, the expression levels of *FDX1*, *LIAS*, and *MTF1* in the GEO database were in line with those in the TCGA cohort, which further supports the merits of application and warrants attention in future research.

**CONCLUSION**

In conclusion, our study systematically analysed the prognostic significance and interactive landscapes of CRGs in GC samples using bioinformatics. The prognostic risk score based on the expression signature of *FDX1*, *LIAS*, and *MTF1* had important implications in the prediction of OS and DSS in GC patients, and these CRGs were associated with infiltration of various immune cell types, providing novel insights into therapeutic strategies for GC patients.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is one of the most common digestive system cancers with high mortality rates worldwide.

***Research motivation***

Cuproptosis is strongly correlated with the biological behaviour of malignant tumour cells and no previous studies have estimated the relationship between cuproptosis related genes (CRGs) and the progression of GC.

***Research objectives***

Our study aims to offer new insights to predict GC prognosis and provide multiple therapeutic targets for future therapy about CRGs.

***Research methods***

We collected data from several public data portals and systematically estimated the expression level and prognostic values of CRGs in GC samples and related mechanisms using public databases and bioinformatics.

***Research results***

We found that *FDX1*, *LIAS*, and *MTF1* were differentially expressed in GC samples and exhibited important prognostic significance. We constructed a nomogram model for overall survival and disease-specific survival prediction and validated it *via* calibration plots. Mechanistically, immune cell infiltration and DNA methylation prominently affected the survival time of GC patients. Moreover, protein-protein interaction network, KEGG pathway and gene ontology enrichment analyses demonstrated that *FDX1*, *LIAS*, *MTF1* and related proteins played key roles in the tricarboxylic acid cycle and cuprotosis. Top 10 perturbagens were filtered as well.

***Research conclusions***

Our findings suggested that *FDX1*, *LIAS*, and *MTF1* had important implications for the prediction of OS and DSS in GC patients, which were associated with various immune cell infiltrations, providing novel insights into therapeutic strategies for GC patients.

***Research perspectives***

Considerable effort needs to be expended in exploring the therapeutic strategies *via* CRGs in GC.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Ding XQ**, Wang ZY, Xia D, Wang RX, Pan XR, Tong JH. Proteomic Profiling of Serum Exosomes From Patients With Metastatic Gastric Cancer. *Front Oncol* 2020; **10**: 1113 [PMID: 32754443 DOI: 10.3389/fonc.2020.01113]

3 **Wang P**, Zhang W, Wang L, Liang W, Cai A, Gao Y, Chen L. RCC2 Interacts with Small GTPase RalA and Regulates Cell Proliferation and Motility in Gastric Cancer. *Onco Targets Ther* 2020; **13**: 3093-3103 [PMID: 32341655 DOI: 10.2147/OTT.S228914]

4 **Tsvetkov P**, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, Rossen J, Joesch-Cohen L, Humeidi R, Spangler RD, Eaton JK, Frenkel E, Kocak M, Corsello SM, Lutsenko S, Kanarek N, Santagata S, Golub TR. Copper induces cell death by targeting lipoylated TCA cycle proteins. *Science* 2022; **375**: 1254-1261 [PMID: 35298263 DOI: 10.1126/science.abf0529]

5 **Hu JD**, Tang HQ, Zhang Q, Fan J, Hong J, Gu JZ, Chen JL. Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. *World J Gastroenterol* 2011; **17**: 727-734 [PMID: 21390142 DOI: 10.3748/wjg.v17.i6.727]

6 **Cerami E**, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012; **2**: 401-404 [PMID: 22588877 DOI: 10.1158/2159-8290.CD-12-0095]

7 **Modhukur V**, Iljasenko T, Metsalu T, Lokk K, Laisk-Podar T, Vilo J. MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data. *Epigenomics* 2018; **10**: 277-288 [PMID: 29264942 DOI: 10.2217/epi-2017-0118]

8 **Anuraga G**, Wang WJ, Phan NN, An Ton NT, Ta HDK, Berenice Prayugo F, Minh Xuan DT, Ku SC, Wu YF, Andriani V, Athoillah M, Lee KH, Wang CY. Potential Prognostic Biomarkers of NIMA (Never in Mitosis, Gene A)-Related Kinase (NEK) Family Members in Breast Cancer. *J Pers Med* 2021; **11** [PMID: 34834441 DOI: 10.3390/jpm11111089]

9 **Xing C**, Wang Z, Zhu Y, Zhang C, Liu M, Hu X, Chen W, Du Y. Integrate analysis of the promote function of Cell division cycle-associated protein family to pancreatic adenocarcinoma. *Int J Med Sci* 2021; **18**: 672-684 [PMID: 33437202 DOI: 10.7150/ijms.53243]

10 **Dwivedi B**, Mumme H, Satpathy S, Bhasin SS, Bhasin M. Survival Genie, a web platform for survival analysis across pediatric and adult cancers. *Sci Rep* 2022; **12**: 3069 [PMID: 35197510 DOI: 10.1038/s41598-022-06841-0]

11 **Hänzelmann S**, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. *BMC Bioinformatics* 2013; **14**: 7 [PMID: 23323831 DOI: 10.1186/1471-2105-14-7]

12 **Li T**, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS. TIMER2.0 for analysis of tumor-infiltrating immune cells. *Nucleic Acids Res* 2020; **48**: W509-W514 [PMID: 32442275 DOI: 10.1093/nar/gkaa407]

13 **Kao TJ**, Wu CC, Phan NN, Liu YH, Ta HDK, Anuraga G, Wu YF, Lee KH, Chuang JY, Wang CY. Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. *Aging (Albany NY)* 2021; **13**: 17970 [PMID: 34329194 DOI: 10.18632/aging.203345]

14 **Laham AJ**, El-Awady R, Lebrun JJ, Ayad MS. A Bioinformatics Evaluation of the Role of Dual-Specificity Tyrosine-Regulated Kinases in Colorectal Cancer. *Cancers (Basel)* 2022; **14** [PMID: 35454940 DOI: 10.3390/cancers14082034]

15 **Warde-Farley D**, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, Maitland A, Mostafavi S, Montojo J, Shao Q, Wright G, Bader GD, Morris Q. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 2010; **38**: W214-W220 [PMID: 20576703 DOI: 10.1093/nar/gkq537]

16 **Szklarczyk D**, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NT, Legeay M, Fang T, Bork P, Jensen LJ, von Mering C. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets. *Nucleic Acids Res* 2021; **49**: D605-D612 [PMID: 33237311 DOI: 10.1093/nar/gkaa1074]

17 **Yu G**, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* 2012; **16**: 284-287 [PMID: 22455463 DOI: 10.1089/omi.2011.0118]

18 **Lamb J**, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* 2006; **313**: 1929-1935 [PMID: 17008526 DOI: 10.1126/science.1132939]

19 **Subramanian A**, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, Khan M, Wadden D, Smith IC, Lam D, Liberzon A, Toder C, Bagul M, Orzechowski M, Enache OM, Piccioni F, Johnson SA, Lyons NJ, Berger AH, Shamji AF, Brooks AN, Vrcic A, Flynn C, Rosains J, Takeda DY, Hu R, Davison D, Lamb J, Ardlie K, Hogstrom L, Greenside P, Gray NS, Clemons PA, Silver S, Wu X, Zhao WN, Read-Button W, Wu X, Haggarty SJ, Ronco LV, Boehm JS, Schreiber SL, Doench JG, Bittker JA, Root DE, Wong B, Golub TR. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. *Cell* 2017; **171**: 1437-1452.e17 [PMID: 29195078 DOI: 10.1016/j.cell.2017.10.049]

20 **Wang CY**, Chiao CC, Phan NN, Li CY, Sun ZD, Jiang JZ, Hung JH, Chen YL, Yen MC, Weng TY, Chen WC, Hsu HP, Lai MD. Gene signatures and potential therapeutic targets of amino acid metabolism in estrogen receptor-positive breast cancer. *Am J Cancer Res* 2020; **10**: 95-113 [PMID: 32064155]

21 **Bartha Á**, Győrffy B. TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. *Int J Mol Sci* 2021; **22** [PMID: 33807717 DOI: 10.3390/ijms22052622]

22 **Acs B**, Ahmed FS, Gupta S, Wong PF, Gartrell RD, Sarin Pradhan J, Rizk EM, Gould Rothberg B, Saenger YM, Rimm DL. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. *Nat Commun* 2019; **10**: 5440 [PMID: 31784511 DOI: 10.1038/s41467-019-13043-2]

23 **Zhang K**, Zhang L, Mi Y, Tang Y, Ren F, Liu B, Zhang Y, Zheng P. A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration. *Cancer Sci* 2020; **111**: 4041-4050 [PMID: 32860283 DOI: 10.1111/cas.14634]

24 **Zhang Y**, Ma S, Wang M, Shi W, Hu Y. Comprehensive Analysis of Prognostic Markers for Acute Myeloid Leukemia Based on Four Metabolic Genes. *Front Oncol* 2020; **10**: 578933 [PMID: 33117716 DOI: 10.3389/fonc.2020.578933]

25 **Zhang J**, Kong X, Zhang Y, Sun W, Wang J, Chen M, Chen X. FDXR regulates TP73 tumor suppressor via IRP2 to modulate aging and tumor suppression. *J Pathol* 2020; **251**: 284-296 [PMID: 32304229 DOI: 10.1002/path.5451]

26 **Wang T**, Liu Y, Li Q, Luo Y, Liu D, Li B. Cuproptosis-related gene *FDX1* expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma. *Front Immunol* 2022; **13**: 999823 [PMID: 36225932 DOI: 10.3389/fimmu.2022.999823]

27 **Burr SP**, Costa AS, Grice GL, Timms RT, Lobb IT, Freisinger P, Dodd RB, Dougan G, Lehner PJ, Frezza C, Nathan JA. Mitochondrial Protein Lipoylation and the 2-Oxoglutarate Dehydrogenase Complex Controls HIF1α Stability in Aerobic Conditions. *Cell Metab* 2016; **24**: 740-752 [PMID: 27923773 DOI: 10.1016/j.cmet.2016.09.015]

28 **Cai Y**, He Q, Liu W, Liang Q, Peng B, Li J, Zhang W, Kang F, Hong Q, Yan Y, Peng J, Xu Z, Bai N. Comprehensive analysis of the potential cuproptosis-related biomarker *LIAS* that regulates prognosis and immunotherapy of pan-cancers. *Front Oncol* 2022; **12**: 952129 [PMID: 35982953 DOI: 10.3389/fonc.2022.952129]

29 **Ruan X**, Zheng J, Liu X, Liu Y, Liu L, Ma J, He Q, Yang C, Wang D, Cai H, Li Z, Liu J, Xue Y. lncRNA LINC00665 Stabilized by TAF15 Impeded the Malignant Biological Behaviors of Glioma Cells via STAU1-Mediated mRNA Degradation. *Mol Ther Nucleic Acids* 2020; **20**: 823-840 [PMID: 32464546 DOI: 10.1016/j.omtn.2020.05.003]

30 **Yang Y**, Qian Cai Q, Sheng Fu L, Wei Dong Y, Fan F, Zhong Wu X. Reduced N6-Methyladenosine Mediated by METTL3 Acetylation Promotes *MTF1* Expression and Hepatocellular Carcinoma Cell Growth. *Chem Biodivers* 2022; **19**: e202200333 [PMID: 36149370 DOI: 10.1002/cbdv.202200333]

31 **Wu L**, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu XO, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng TD, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghoussaini M, Giles GG, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma VM, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo WY, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, Mavroudis D, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott CG, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar RAEM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E; kConFab/AOCS Investigators, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nat Genet* 2018; **50**: 968-978 [PMID: 29915430 DOI: 10.1038/s41588-018-0132-x]

32 **Li P**, Bai C, Zhan L, Zhang H, Zhang Y, Zhang W, Wang Y, Zhao J. Specific gene module pair-based target identification and drug discovery. *Front Pharmacol* 2022; **13**: 1089217 [PMID: 36726786 DOI: 10.3389/fphar.2022.1089217]

**Footnotes**

**Institutional review board statement:** Our research is based on the Cancer Genome Atlas (TCGA, https://tega-data.nci.nih.gov/) database, the Genotype-Tissue Expression (GTEx) data portal (https://www.gtexportal.org/home/index.html) and the Gene Expression Omnibus (GEO, https://www.nebi.nlm.nih.gov/gds) database. All of these are open-access public databases. Thus, no institutional review board approval was required.

**Conflict-of-interest statement:** All the authors report having no relevant conflicts of interest for this article.

**Data sharing statement:** The technical appendix, statistical code, and datasets are available from the corresponding author at fyshaoyongfu@nbu.edu.cn.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 4, 2023

**First decision:** March 21, 2023

**Article in press:** May 6, 2023

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0


**P-Reviewer:** Casella C, Italy; Wang CY, Taiwan **S-Editor:** Li L **L-Editor:** Filipodia **P-Editor:** Ji MX

**Figure Legends**


图形用户界面, 散点图

描述已自动生成


**Figure 1 Cuproptosis-related gene expression status in gastric cancer.** A: Expression levels of 19 human cuproptosis-related genes (CRGs) in gastric cancer tissues and corresponding normal tissues in the Cancer Genome Atlas database; B: Correlations between the expression of 16 differential CRGs in gastric cancer; C: Overall landscape of gene mutations of differential CRGs in gastric cancer; D: Patterns of gene mutation of differentially expressed CRGs in gastric cancer (a*P* < 0.05, b*P* < 0.01, c*P* < 0.001). NS: Not significant.




**Figure 2 Clinical significance of prognostic cuproptosis-related genes in gastric cancer in the Cancer Genome Atlas cohort.** A: Distribution of risk score, overall survival (OS) status and the expression of *FDX1* and *MTF1* in gastric cancer (GC) patients; B: Distribution of risk score, disease-specific survival (DSS) status and the expression of *FDX1* and *MTF1* in GC patients; C: Kaplan-Meier curves of the expression of *FDX1*, *LIAS*, *MTF1* and OS time; D: Kaplan-Meier curves of the expression of *FDX1*, *LIAS*, and *MTF1* and DSS time.




**Figure 3 Overall survival nomogram model and calibration plots.** A: Prognostic nomogram plot constructed to predict the 1-, 3-, and 5-year overall survival (OS) times of gastric cancer patients in The Cancer Genome Atlas (TCGA) cohort; B: Prognostic nomogram plot constructed to predict the 1-, 3-, and 5-year disease-specific survival (DSS) times of gastric cancer patients in the TCGA cohort; C: Calibration plot of the nomogram for 1-, 3-, and 5-year OS time; D: Calibration plot of the nomogram for 1-, 3-, and 5-year DSS time.



**Figure 4 Relationship between the expression of prognostic cuproptosis-related genes and immune cell infiltration levels in gastric cancer.** A-C: Kaplan-Meier curves of the expression of *FDX1* (A), *LIAS* (B), *MTF1* (C) in scRNA-seq samples and immune cell infiltration level groups. All of these genes were correlated with the overall survival time of gastric cancer patients; D-F: The correlation of different immune cell infiltration levels and the expression of FDX (D), *LIAS* (E), and *MTF1* (F) in scRNA-seq samples; G-I: Lollipop plots of different immune cell infiltration levels and the expression of FDX (G), *LIAS* (H), and *MTF1* (I). The length of the bars in the lollipop plots is relative to the correlation levels, and the color of the cycles is relative to the *P* value; J-L: Lower levels of methylation in *FDX1* (J) and higher levels of methylation in *LIAS* (K), *MTF1* (L) are associated with poor prognosis. HR: Hazard ratio; STAD: Stomach adenocarcinoma; TCGA: The Cancer Genome Atlas.



**Figure 5 Analysis of the biological functions of prognostic cuproptosis-related genes.** A: Gene network associated with *FDX1*, *LIAS*, and *MTF1* containing 23 related genes, constructed using GeneMANIA. The different colors of the lines are associated with the different functions; B: Protein-protein interaction network diagram of interactions between proteins encoded by genes related to *FDX1*, *LIAS*, and *MTF1* constructed using GeneMANIA and STRING; C: KEGG pathway enrichment analysis and gene ontology classification of several targets from STRING. BP: Biological process; CC: Cellular component; MF: Molecular function.



**Figure 6 Differential expression analysis and validation of prognostic cuproptosis-related genes in the TNM plot database.** A: *FDX1* was remarkably overexpressed in gastric cancer (GC) cancer samples in the Gene Expression Omnibus (GEO) in the TNM plot database; B: *LIAS* was remarkably downregulated in GC cancer samples in GEO in the TNM plot database; C: *MTF1* was remarkably overexpressed in GC cancer samples in GEO in the TNM plot database.

**Table 1 Univariate and multivariate analysis of the correlation of differentially expressed cuproptosis-related gene expression with overall survival among gastric cancer patients**

| **Gene** | **Total, *n*** | **Univariate analysis** | | **Multivariate analysis** | |
| --- | --- | --- | --- | --- | --- |
| **Hazard ratio (95%CI)** | ***P* value** | **Hazard ratio (95%CI)** | ***P* value** |
| *ATP7A* | 370 | 1.037 (0.725-1.483) | 0.842 |  |  |
| *ATP7B* | 370 | 0.922 (0.781-1.088) | 0.334 |  |  |
| *CDKN2A* | 370 | 0.985 (0.887-1.094) | 0.782 |  |  |
| *DLAT* | 370 | 0.785 (0.577-1.069) | 0.124 |  |  |
| *DLD* | 370 | 0.961 (0.678-1.363) | 0.825 |  |  |
| *FDX1* | 370 | 0.737 (0.533-1.018) | 0.064 | 0.735 (0.534-1.011) | 0.059 |
| *GCSH* | 370 | 1.054 (0.769-1.446) | 0.744 |  |  |
| *GLS* | 370 | 1.052 (0.845-1.310) | 0.650 |  |  |
| *LIAS* | 370 | 0.730 (0.498-1.068) | 0.105 |  |  |
| *LIPT1* | 370 | 1.168 (0.713-1.916) | 0.537 |  |  |
| *LIPT2* | 370 | 1.014 (0.794-1.294) | 0.912 |  |  |
| *MTF1* | 370 | 0.642 (0.410-1.006) | 0.053 | 0.661 (0.411-1.064) | 0.088 |
| *NFE2L2* | 370 | 0.701 (0.477-1.031) | 0.071 | 0.809 (0.534-1.225) | 0.317 |
| *NLRP3* | 370 | 1.279 (0.946-1.729) | 0.110 |  |  |
| *PDHA1* | 370 | 0.873 (0.632-1.206) | 0.409 |  |  |
| *PDHB* | 370 | 1.051 (0.686-1.611) | 0.818 |  |  |
| *SLC31A1* | 370 | 0.834 (0.653-1.065) | 0.146 |  |  |

CI: Confidence interval.

**Table 2 Univariate and multivariate analysis of the correlation of differentially expressed cuproptosis-related gene expression with disease-specific survival among gastric cancer patients**

| **Gene** | **Total, *n*** | **Univariate analysis** | | **Multivariate analysis** | |
| --- | --- | --- | --- | --- | --- |
| **Hazard ratio (95%CI)** | ***P* value** | **Hazard ratio (95%CI)** | ***P* value** |
| *ATP7A* | 349 | 1.032 (0.656-1.625) | 0.891 |  |  |
| *ATP7B* | 349 | 0.957 (0.776-1.180) | 0.680 |  |  |
| *CDKN2A* | 349 | 1.019 (0.894-1.162) | 0.774 |  |  |
| *DLAT* | 349 | 0.701 (0.471-1.043) | 0.080 | 1.185 (0.708-1.982) | 0.518 |
| *DLD* | 349 | 0.657 (0.415-1.039) | 0.072 | 0.926 (0.529-1.622) | 0.788 |
| *FDX1* | 349 | 0.668 (0.441-1.013) | 0.057 | 0.722 (0.448-1.164) | 0.181 |
| *GCSH* | 349 | 1.280 (0.863-1.900) | 0.220 |  |  |
| *GLS* | 349 | 1.041 (0.788-1.376) | 0.778 |  |  |
| *LIAS* | 349 | 0.509 (0.310-0.836) | 0.008 | 0.578 (0.338-0.989) | 0.045 |
| *LIPT1* | 349 | 1.117 (0.594-2.101) | 0.731 |  |  |
| *LIPT2* | 349 | 1.014 (0.745-1.381) | 0.928 |  |  |
| *MTF1* | 349 | 0.581 (0.329-1.023) | 0.060 | 0.604 (0.321-1.135) | 0.117 |
| *NFE2L2* | 349 | 0.584 (0.360-0.947) | 0.029 | 0.709 (0.414-1.215) | 0.211 |
| *NLRP3* | 349 | 1.082 (0.716-1.634) | 0.710 |  |  |
| *PDHA1* | 349 | 0.676 (0.441-1.036) | 0.072 | 0.780 (0.469-1.297) | 0.338 |
| *PDHB* | 349 | 0.809 (0.465-1.408) | 0.454 |  |  |
| *SLC31A1* | 349 | 0.768 (0.564-1.046) | 0.094 | 1.029 (0.717-1.476) | 0.878 |

CI: Confidence interval.

**Table 3 Potential perturbagens of interactive prognostic cuproptosis-related genes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Perturbagen** | **Moa** | **Raw\_cs** | **FDR\_q\_nlog 10** |
| Fluconazole | Sterol demethylase inhibitor | 0.79 | 1.03 |
| KD-025 | Rho associated kinase inhibitor | 0.77 | 0.95 |
| Clofarabine | Ribonucleoside reductase inhibitor | 0.76 | 0.89 |
| Tramadol | Opioid receptor agonist, Norepinephrine reuptake inhibitor, Serotonin reuptake inhibitor | 0.76 | 0.89 |
| Doxorubicin | Topoisomerase inhibitor | 0.75 | 0.88 |
| AXD-5438 | CDK inhibitor | 0.73 | 0.80 |
| BRD-K67174965 | Mucolytic | 0.73 | 0.79 |
| Faropenem | Lactamase inhibitor | 0.72 | 0.76 |
| Clocortolone-pivalate | Steroid | 0.72 | 0.68 |
| Ganglioside | Src activator | 0.71 | 0.46 |



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**